BIRC5 and breast cancer: successfully validated their biomarker-based risk score (galectin-3, CD44, E-cadherin, CD138, p16, Survivin, HYAL-1 and topoisomerase-IIα) with the purpose of improving the EORTC risk stratification for patients with a single T1 HG BC of less than 3 cm in diameter.